New drug shows promise for fatty liver in small trial

NCT ID NCT00666016

First seen Dec 26, 2025 · Last updated Jun 13, 2026 · Updated 22 times

Summary

This study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took the drug or a placebo for one month to see if it improved liver enzyme levels and was safe. The goal was to gather early information on whether the drug might help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU AMIENS, Service d'Hépato-Gastroentérologie

    Amiens, 80054, France

  • Centre Hospitalier de Hyères, Hôpital de Jour, Service d'Hépato-Gastro-Entérologie

    Hyères, 83407, France

  • Groupe Hospitalier Pitié-Salpétrière - Sce Hépato-Gastroentérologie - 47-83 Bd de l'Hôpital

    Paris, 75651, France

  • Hôpital Archet 2 - Pôle de Référence Hépatite C (Niveau -2) - 151, route Saint Antoine de Ginestière

    Nice, 06200, France

  • Hôpital Saint Joseph, Service d'Hépato-Gastro-Entérologie

    Marseille, 13285, France

Conditions

Explore the condition pages connected to this study.